Literature DB >> 21052780

Acquired factor V inhibitors: a systematic review.

Massimo Franchini1, Giuseppe Lippi.   

Abstract

The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bovine thrombin administered during surgery procedures. However, since this preparation is no longer used, in this systematic review we have only focused on non-bovine thrombin-related FV inhibitor cases.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21052780     DOI： 10.1007/s11239-010-0529-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  89 in total

Review 1.  Clinical and laboratory manifestations of anti-factor V antibodies.

Authors:  T L Ortel
Journal:  J Lab Clin Med       Date:  1999-04

Review 2.  [Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention].

Authors:  D Massignon; S Roullit; D Espinouse; P Coeur
Journal:  Ann Fr Anesth Reanim       Date:  1989

3.  Thrombin generation assay in a patient with acquired factor V inhibitor.

Authors:  S Kindler; T Siegemund; D Führer; S Petros
Journal:  J Thromb Haemost       Date:  2008-09-09       Impact factor: 5.824

4.  Acquired factor V inhibitor in a critically ill patient.

Authors:  C J Morris; N Curry
Journal:  Anaesthesia       Date:  2009-09       Impact factor: 6.955

5.  Factor V inhibitor and bullous pemphigoid.

Authors:  K Bryning; J Leslie
Journal:  Br Med J       Date:  1977-09-10

6.  Massive hemorrhage associated with circulating antibodies to factor V.

Authors:  C A Onuora; J Lindenbaum; H L Nossel
Journal:  Am J Med Sci       Date:  1973-05       Impact factor: 2.378

7.  Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.

Authors:  J Chediak; J B Ashenhurst; I Garlick; R K Desser
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

8.  Factor V anticoagulants: clinical, biochemical, and immunological observations.

Authors:  D I Feinstein; S I Rapaport; W G McGehee; M J Patch
Journal:  J Clin Invest       Date:  1970-08       Impact factor: 14.808

Review 9.  Acquired factor V inhibitor. A problem-based systematic review.

Authors:  Ai Leen Ang; Ponnudurai Kuperan; Chin Hin Ng; Heng Joo Ng
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

10.  Successful treatment with rituximab in a patient with an acquired factor V inhibitor.

Authors:  Agnes Lebrun; Catherine Leroy-Matheron; Jean-Benoit Arlet; Pablo Bartolucci; Marc Michel
Journal:  Am J Hematol       Date:  2008-02       Impact factor: 10.047
View more
  29 in total

1.  Complete response of acquired FV inhibitor to rituximab.

Authors:  Edmond S K Ma; Raymond H S Liang; Kent-Man Chu; George K K Lau
Journal:  Int J Hematol       Date:  2015-01-24       Impact factor: 2.490

2.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Authors:  Massimo Franchini; Giancarlo Castaman; Antonio Coppola; Cristina Santoro; Ezio Zanon; Giovanni Di Minno; Massimo Morfini; Elena Santagostino; Angiola Rocino
Journal:  Blood Transfus       Date:  2015-06-24       Impact factor: 3.443

3.  Acquired factor V deficiency in a patient without evidence of a classical inhibitor.

Authors:  I R Sosa; P Ellery; A Mast; A T Neff; D Gailani
Journal:  Haemophilia       Date:  2013-10-14       Impact factor: 4.287

4.  Acquired factor v inhibitor developing after treatment with dabigatran etexilate methanesulfonate: a case report and review of the literature.

Authors:  Yasunobu Sekiguchi; Hitomi Yoshikawa; Asami Shimada; Hidenori Imai; Mutsumi Wakabayashi; Keiji Sugimoto; Noriko Nakamura; Tomohiro Sawada; Tetsuo Ichinose; Dai Ozaki; Norio Komatsu; Masaaki Noguchi
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-06       Impact factor: 0.900

5.  Management of rare acquired bleeding disorders.

Authors:  Marzia Menegatti; Eugenia Biguzzi; Flora Peyvandi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Transient cefuroxime/metronidazole treatment induced factor V antibodies.

Authors:  Sjoerd Adrianus Antonius Van den Berg; Patricia E Verwer; René N Idema; Coen Van Guldener
Journal:  BMJ Case Rep       Date:  2014-08-19

7.  Laparoscopic hepatectomy for hepatocellular carcinoma in a patient with congenital factor V deficiency: a case report.

Authors:  Takaomi Seki; Mariko Tsukagoshi; Norifumi Harimoto; Kenichiro Araki; Akira Watanabe; Norihiro Ishii; Kei Hagiwara; Kouki Hoshino; Ryo Muranushi; Satoru Kakizaki; Yoshiyuki Ogawa; Hiroshi Handa; Ken Shirabe
Journal:  Surg Case Rep       Date:  2022-10-22

8.  Bleeding associated with acquired factor V inhibitor in a patient on warfarin treated successfully with prednisolone.

Authors:  Alhossain Khalafallah; Julian Grabek; Robert Hayes; Muhajir Mohamed
Journal:  BMJ Case Rep       Date:  2013-08-06

9.  Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.

Authors:  Kaisei Kamatani; Tsuneaki Kenzaka; Ryu Sugimoto; Ayako Kumabe; Akihito Kitao; Hozuka Akita
Journal:  BMC Infect Dis       Date:  2021-06-05       Impact factor: 3.090

10.  A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors.

Authors:  Yasuko Kadohira; Shinya Yamada; Tomoe Hayashi; Eriko Morishita; Hidesaku Asakura; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-04-02       Impact factor: 2.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.